Home » REXAHN PHARMACEUTICALS: A YEAR-IN-REVIEW
REXAHN PHARMACEUTICALS: A YEAR-IN-REVIEW
From a public company merger to the orphan drug designation of one of its leading
cancer drug candidates, Rexahn Pharmaceuticals, (RXHN.OB), a clinical stage
pharmaceutical company, has much to be proud of as it reflects on 2005 and looks
forward to the year ahead. Based in Rockville, Maryland, Rexahn is a pharmaceutical
company dedicated to the discovery, development, and commercialization of innovative
treatments for cancer and disorders of the central nervous system.
Genetic
Engineering News
KEYWORDS FDAnews Drug Daily Bulletin
Upcoming Events
-
25Apr
-
07May
-
14May
-
30May